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Abstract
Over the past several years, tumor necrosis factor (TNF) antagonists have become first-line agents in
the treatment of moderate-to-severe psoriasis. These medications are highly effective in treating both
psoriasis and psoriatic arthritis and may also reduce the risk of cardiovascular events in patients with
chronic inflammatory disorders. In this article we review the use of anti-TNF therapy in psoriasis and
its implications in regards to the co-morbid conditions associated with psoriasis.
Introduction and context
Psoriasis is a common, chronic inflammatory disease of
the skin affecting 1–3% of the general population and
characterized by complex alterations in epidermal
growth and differentiation with multiple biochemical,
immunological, and vascular abnormalities [1].
Although the exact etiology of psoriasis remains unclear,
current evidence indicates that it is T-cell driven.
Individuals with active skin disease have elevated levels
of tumor necrosis factor alpha (TNFa) in both blood and
lesional skin [2]. TNFa, which is secreted by both T cells
and antigen-presenting cells within lesional skin, has
emerged as a key mediator in the disease process.
Specifically, TNFa is a pro-inflammatory cytokine that
amplifies inflammation through several distinct path-
ways: facilitating entry of inflammatory cells into
lesional skin through induction of adhesion molecules
on vascular endothelial cells; stimulating keratinocyte
production of other pro-inflammatory mediators [3];
and finally activating dermal macrophages and dendritic
cells (Figure 1). Recently, the efficacy of TNFa inhibitors
in treating psoriasis has been attributed to their inhibi-
tion of Th17 T-cells [2], a newly identified population
of T cells now thought to be central to psoriasis
pathogenesis.
Currently, three TNFa antagonists are available for use in
psoriasis: infliximab (Remicade®), etanercept (Enbrel®),
and adalimumab (Humira®). While all three block
TNFa in vivo, they differ significantly in structure and
exact mechanism of action. Infliximab is a chimeric
human/murine monoclonal antibody that can bind
both soluble and membrane-bound TNFa and effec-
tively neutralize its activity [4]. Adalimumab, a fully
human antibody [5], functions in the same way as
infliximab, binding both soluble and membrane bound
TNFa. In contrast, etanercept is a receptor fusion protein
and is composed of two human TNFa receptors fused to
the Fc portion of a human antibody. Etanercept binds
free TNFa and weakly inhibits TNFa trimers in vivo [4].
Of these three antagonists, etanercept is the least effective
[6]. Infliximab, due to its non-human (chimeric)
structure, carries higher risk of inducing neutralizing
antibodies, particularly in patients on intermittent
therapy, and this can lead to decreased efficacy and
lack of response to treatment [7]. Consequently, some
dermatologists recommend concomitantly treating
patients with methotrexate [8–13], although no clear
guidelines exist.
As mentioned above, there is a slight difference in the
way that these agents work. Additionally, the dosing
regimens for these three agents differ significantly
Page 1 of 4
(page number not for citation purposes)
Published: 08 May 2009
© 2009 Medicine Reports Ltd
new implications
for associated comorbidities
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,(Figure 2 and Table 1). TNF antagonists cause immuno-
suppression and are contraindicated in patients with
chronic leg ulcers, persistent or recurrent chest infections,
indwelling catheters, demyelinating diseases, congestive
cardiac failure (New York Heart Association classes III
and IV) and malignancy (except adequately treated
non-melanoma skin cancer) [14]. Latent tuberculosis
can also reactivate during treatment, although this has
been shown to be lower for etanercept [12] compared to
the other two agents. Therefore, patients with untreated
or latent tuberculosis should receive a full 9-month
course of isoniazid before initiating treatment with TNF
antagonists [12]. Furthermore, screening with the tuber-
culin skin test is recommended in all individuals prior to
treatment [12], and patients receiving treatment are
encouraged to undergo yearly tuberculosis screenings for
the duration of the regimen [12].
Due to the substantial cost and risks associated with
TNF-inhibitor therapy, several guidelines have been
published for their use in psoriasis [5,12]. It is
recommended that these agents only be used in patients
with extensive skin disease or in patients with limited
Table 1. Clinical guidelines for TNF inhibitor use [5]
Infliximab Adalimumab Etanercept
Administration Intravenous infusion Subcutaneous injection Subcutaneous injection
Dosing schedule
Induction Weeks 0, 2, 6 = 5 mg/kg Week 0 = 80 mg Months 0–2 = 50 mg twice weekly
Week 1 = 40 mg
Maintenance Every 8 weeks = 5 mg/kg Every 2 weeks = 40 mg Every week = 50 mg
Efficacy
Short-term 10 weeks: 80% of patients = PASI-75 12 weeks: 80% of patients = PASI-75 12 weeks: 49% of patients = PASI-75
Long-term 50 weeks: 61% of patients = PASI-75 60 weeks: 68% of patients = PASI-75 59% of patients = PASI-75
Baseline monitoring
Required PPD PPD PPD
Recommended LFT, CBC, hepatitis panel LFT, CBC, hepatitis panel LFT, CBC, hepatitis panel
Ongoing monitoring
Recommended Yearly PPD Yearly PPD Yearly PPD
Periodic history and physical Periodic history and physical Periodic history and physical
Periodic LFT, CBC Periodic LFT, CBC Periodic LFT, CBC
Pregnancy class B B B
Toxicities
Common Serum sickness Injection site reaction/pain Injection site reaction/pruritis
Infusion reaction Flu-like symptoms Flu-like symptoms
Rare Serious infection (TB) Serious infection (TB) Serious infection (TB)
Lymphoma Lymphoma Lymphoma
New onset CHF, lupus, MS, cytopenia New onset CHF, lupus, MS, cytopenia New onset CHF, lupus, MS, cytopenia
Cancer Cancer Cancer
CBC, complete blood count; CHF, congestive heart failure; LFT, liver function test; MS, multiple sclerosis; PASI, Psoriasis Area and Severity Index; PPD,
purified protein derivative test; TB, tuberculosis; TNF, tumor necrosis factor.
Figure 1. The biological effects of TNFa [27]
IL, interleukin; TNF, tumor necrosis factor.
Figure 2. Dosing regimens for the three TNF antagonists
Infliximab (5 mg/kg) is given through intravenous infusion at weeks 0, 2, and
6 and every 8 weeks thereafter as a maintenance. Adalimumab is initially
given as a single 80 mg subcutaneous injection at week 0, 40 mg at week 1
and then every other week as a maintenance. Etanercept is given
subcutaneously, usually in a 50 mg dose twice weekly for 12 weeks and then
weekly as a maintenance. TNF, tumor necrosis factor.
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phototherapy. There are limited data regarding the use of
these medications in children except for etanercept
[5,13].
Recent advances
Over the past several years it has become apparent that
psoriasis is associated with several co-morbidities,
including lymphoma [14], myocardial infarction [15],
and metabolic diseases such as obesity, diabetes, and
hypertension [16]. The risk of these co-morbid condi-
tions appears to be higher in individuals with more
severe disease [14,15] and, not surprisingly, psoriasis has
been associated with increased mortality [17]. While the
majority of affected individuals are successfully managed
with topical therapies, 20–30% of cases have severe
extensive disease necessitating systemic treatment [7].
It remains unclear whether treatment with systemic
agents can decrease the risk of co-morbid conditions
associated with psoriasis. This is still a largely unexplored
area of research in psoriasis, but several recently
published studies have begun to provide some insights
into this problem. Psoriasis has a complex relationship
with metabolic diseases such as obesity [16]. Adipose
tissue, including adipocytes and resident macrophages,
may serve as a significant source of TNFa in obese
individuals [16,18,19]. This source of circulating TNFa
can create a pro-inflammatory state elsewhere in the
body and can further amplify pre-existing inflammatory
processes. Moreover, elevated levels of TNFa have also
been suggested to disrupt normal adipocyte function,
ultimately leading to increased total body adiposity and
further metabolic dysregulation [19]. It is not surprising,
therefore, that a correlation between body mass and
psoriasis has been identified and obese patients seem to
have decreased responses to systemic treatments [20].
Interestingly, TNF antagonists may also contribute to
obesity [21–23]. Due to the association between obesity
and higher levels of circulating TNFa [24], the efficacy of
fixed dose anti-TNF agents (etanercept and adalimumab)
has been questioned in obese individuals [25].
Few studies exist on whether TNF antagonists have any
effect on glucose control. In a recent study of 12 psoriasis
patients with two or more risk factors for type 2 diabetes
mellitus, treatment with etanercept was shown to slightly
lower fasting insulin levels [26]. However, no difference
was seen in insulin secretion and insulin sensitivity while
on treatment [26].
As more evidence emerges correlating elevated C-reactive
protein levels directly with increased risk of cardiovas-
cular disease, suppressing chronic inflammation has
become a top priority in the treatment of psoriasis. Since
TNFa is a recognized mediator of systemic inflamma-
tion, it has been hypothesized that TNF antagonists may
have cardioprotective properties [25]. Although insuffi-
cient data exist to reach any definitive conclusions in this
regard, one recent study demonstrated that etanercept
significantly reduced C-reactive protein levels in obese
patients with moderate-to-severe plaque psoriasis, indi-
cating that adequately treated patients may have
decreased risk for future cardiovascular events [18].
However, it is not clear whether this ‘protective’ effect
lasts once treatment is discontinued.
Implications for clinical practice
Anti-TNFa antagonists continue to be one of the most
effective medications in treating psoriasis, significantly
decreasing the overall burden of the disease. Further-
more, with recent data suggesting that these drugs may
decrease cardiovascular risk in patients with chronic
inflammatory diseases, TNF antagonists may play a
larger role in psoriasis treatment in the future. However,
given the potential risks of infection and malignancy, the
use of these agents should be carefully evaluated.
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